Read by QxMD icon Read


Hnin Su Su Khin, Tin Aung, Moe Aung, Aung Thi, Matt Boxshall, Chris White
BACKGROUND: In 2012, alarmingly high rates of oral artemisinin monotherapy availability and use were detected along Eastern Myanmar, threatening efforts to halt the spread of artemisinin resistance in the Greater Mekong Subregion (GMS), and globally. The aim of this paper is to exemplify how the use of supply side evidence generated through the ACTwatch project shaped the artemisinin monotherapy replacement malaria (AMTR) project's design and interventions to rapidly displace oral artemisinin monotherapy with subsidized, quality-assured ACT in the private sector...
2016: Malaria Journal
Hnin Su Su Khin, Tin Aung, Aung Thi, Chris White
BACKGROUND: In 2012 the Artemisinin Monotherapy Therapy Replacement (AMTR) project was implemented in Eastern Myanmar to increase access to subsidized, quality-assured artemisinin combination therapy (ACT) and to remove oral artemisinin monotherapy (AMT) from the private sector. The aim of this paper is to examine changes over time in the private sector anti-malarial landscape and to illustrate the value of complementary interventions in the context of a national ACT subsidy. METHODS: Three rounds of cross-sectional malaria medicine outlet surveys were conducted, in 2012, 2013 and 2014...
2016: Malaria Journal
Joe Novotny, Amandeep Singh, Lek Dysoley, Siv Sovannaroth, Huy Rekol
BACKGROUND: For over a decade, Cambodia has implemented a number of policies and innovative strategies to increase access to quality malaria case management services and address the drivers of multi-drug resistance. This paper utilizes outlet survey trend data collected by the ACTwatch project to demonstrate how changes in Cambodian policy and strategies have led to shifts in anti-malarial markets. METHODS: Anti-malarial ACTwatch outlet surveys were conducted in Cambodia in 2009 (June-July), 2011 (June-August) and 2013 (September-October)...
2016: Malaria Journal
Stephen Poyer, Tanya Shewchuk, Sarah Tougher, Yazoume Ye, Andrea G Mann, Barbara A Willey, Rebecca Thomson, John H Amuasi, Ruilin Ren, Marilyn Wamukoya, Mark Taylor, Samuel Blay Nguah, Blessing Mberu, Admirabilis Kalolella, Elizabeth Juma, Charles Festo, Boniface Johanes, Graciela Diap, Katia Bruxvoort, Daniel Ansong, Kara Hanson, Fred Arnold, Catherine Goodman
OBJECTIVES: To describe the state of the public and private malaria diagnostics market shortly after WHO updated its guidelines for testing all suspected malaria cases prior to treatment. METHODS: Ten nationally representative cross-sectional cluster surveys were conducted in 2011 among public and private health facilities, community health workers and retail outlets (pharmacies and drug shops) in nine countries (Tanzania mainland and Zanzibar surveyed separately)...
June 2015: Tropical Medicine & International Health: TM & IH
Sarah Tougher, Andrea G Mann, Yazoume Ye, Idrissa A Kourgueni, Rebecca Thomson, John H Amuasi, Ruilin Ren, Barbara A Willey, Daniel Ansong, Katia Bruxvoort, Graciela Diap, Charles Festo, Boniface Johanes, Admirabilis Kalolella, Oumarou Mallam, Blessing Mberu, Salif Ndiaye, Samual Blay Nguah, Moctar Seydou, Mark Taylor, Marilyn Wamukoya, Fred Arnold, Kara Hanson, Catherine Goodman
Improving access to quality-assured artemisinin combination therapies (ACTs) is an important component of malaria control in low- and middle-income countries. In 2010 the Global Fund to Fight AIDS, Tuberculosis, and Malaria launched the Affordable Medicines Facility--malaria (AMFm) program in seven African countries. The goal of the program was to decrease malaria morbidity and delay drug resistance by increasing the use of ACTs, primarily through subsidies intended to reduce costs. We collected data on price and retail markups on antimalarial medicines from 19,625 private for-profit retail outlets before and 6-15 months after the program's implementation...
September 2014: Health Affairs
Kathryn A O'Connell, Stephen Poyer, Tsione Solomon, Erik Munroe, Edith Patouillard, Julius Njogu, Illah Evance, Kara Hanson, Tanya Shewchuk, Catherine Goodman
BACKGROUND: In recent years an increasing number of public investments and policy changes have been made to improve the availability, affordability and quality of medicines available to consumers in developing countries, including anti-malarials. It is important to monitor the extent to which these interventions are successful in achieving their aims using quantitative data on the supply side of the market. There are a number of challenges related to studying supply, including outlet sampling, gaining provider cooperation and collecting accurate data on medicines...
2013: Malaria Journal
Sarah Tougher, Yazoume Ye, John H Amuasi, Idrissa A Kourgueni, Rebecca Thomson, Catherine Goodman, Andrea G Mann, Ruilin Ren, Barbara A Willey, Catherine A Adegoke, Abdinasir Amin, Daniel Ansong, Katia Bruxvoort, Diadier A Diallo, Graciela Diap, Charles Festo, Boniface Johanes, Elizabeth Juma, Admirabilis Kalolella, Oumarou Malam, Blessing Mberu, Salif Ndiaye, Samuel B Nguah, Moctar Seydou, Mark Taylor, Sergio Torres Rueda, Marilyn Wamukoya, Fred Arnold, Kara Hanson
BACKGROUND: Malaria is one of the greatest causes of mortality worldwide. Use of the most effective treatments for malaria remains inadequate for those in need, and there is concern over the emergence of resistance to these treatments. In 2010, the Global Fund launched the Affordable Medicines Facility--malaria (AMFm), a series of national-scale pilot programmes designed to increase the access and use of quality-assured artemisinin based combination therapies (QAACTs) and reduce that of artemisinin monotherapies for treatment of malaria...
December 1, 2012: Lancet
Kathryn A O'Connell, Hellen Gatakaa, Stephen Poyer, Julius Njogu, Illah Evance, Erik Munroe, Tsione Solomon, Catherine Goodman, Kara Hanson, Cyprien Zinsou, Louis Akulayi, Jacky Raharinjatovo, Ekundayo Arogundade, Peter Buyungo, Felton Mpasela, Chérifatou Bello Adjibabi, Jean Angbalu Agbango, Benjamin Fanomezana Ramarosandratana, Babajide Coker, Denis Rubahika, Busiku Hamainza, Steven Chapman, Tanya Shewchuk, Desmond Chavasse
BACKGROUND: Artemisinin-based combination therapy (ACT) is the first-line malaria treatment throughout most of the malaria-endemic world. Data on ACT availability, price and market share are needed to provide a firm evidence base from which to assess the current situation concerning quality-assured ACT supply. This paper presents supply side data from ACTwatch outlet surveys in Benin, the Democratic Republic of Congo (DRC), Madagascar, Nigeria, Uganda and Zambia. METHODS: Between March 2009 and June 2010, nationally representative surveys of outlets providing anti-malarials to consumers were conducted...
2011: Malaria Journal
Tanya Shewchuk, Kathryn A O'Connell, Catherine Goodman, Kara Hanson, Steven Chapman, Desmond Chavasse
BACKGROUND: Policy makers, governments and donors are faced with an information gap when considering ways to improve access to artemisinin-based combination therapy (ACT) and malaria diagnostics including rapid diagnostic tests (RDTs). To help address some of these gaps, a five-year multi-country research project called ACTwatch was launched. The project is designed to provide a comprehensive picture of the anti-malarial market to inform national and international anti-malarial drug policy decision-making...
2011: Malaria Journal
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"